louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06327971: Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
Official title: Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Squamous Cell Carcinoma of the Skin
Lead sponsor: Queen Mary University of London
Sponsor class: OTHER
First posted: 2024-03-25
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults

Brief summary: Evaluate a deep-learning model trained on computational histopathology for predicting outcomes in cutaneous squamous cell carcinoma


Eligibility criteria: Histologically-confirmed diagnosis of primary cutaneous squamous cell carcinoma

Primary outcomes:
measure: Metastasis
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Barts Health NHS Trust
Study officials:
References:
Clinical trial NCT01031771: Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy
Official title: Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Palsy
Deglutition Disorders
Keywords: Cerebral Palsy
Deglutition
Deglutition disorders
Endoscopy
Lead sponsor: Fortaleza University
Sponsor class: OTHER
First posted: 2009-12-15
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with Cerebral Palsy diagnoses

Brief summary: The purpose of this study is to correlate the alimentary consistencies and deglutition disorders in children with cerebral palsy.

Detailed description: Cross-sectional and quantitative study with sample consisted of 50 children with cerebral palsy. The data collection consisted in detection of the main dysphagic manifestations in different consistency of food and types of cerebral palsy.

Eligibility criteria: Inclusion Criteria:

* Children with Cerebral Palsy diagnoses were involved, independent from the pre, peri and postnatal factors and from the type of Cerebral Palsy

Exclusion Criteria:

* Children who presented oropharyngelarynx structural abnormality and/or impossibility to feed by oral way

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Fortaleza University
name: Moisés A Queiroz, Graduate
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05962671: Opioid-sparing Versus Sevoflurane Anesthesia on Early Postoperative Hypoventilation in Laparoscopic Bariatric Surgery
Official title: Opioid-sparing Versus Sevoflurane-based Anesthesia on Early Postoperative Hypoventilation in Patients Undergoing Laparoscopic Bariatric Surgery: Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Anesthesia
Hypoventilation
Opioid Use
Bariatric Surgery
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2023-07-27
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Determine the incidence of early post-operative hypoventilation in post-anesthesia care unit (PACU) in patients undergoing laparoscopic bariatric surgery under opioid-sparing compared with sevoflurane-based anesthesia.

Detailed description: The incidence of early postoperative hypoxemia in the literature is diverse, this may be due to multivariable, including patient-related factors, anesthesia-related factors, and surgery-related factors. Because of the controverse regarding the incidence of postoperative hypoxemia and the evidence of anesthetic technique of choice, interest in prevention and early management of early postoperative hypoxemia after laparoscopic bariatric surgery is continued.

Eligibility criteria: Inclusion Criteria:

* All adult patients ≥ 18 years
* Admitted to the post anesthesia care unit after bariatric surgery

Exclusion Criteria:

• Preoperative hypoxemia which is determined by a peripheral capillary oxygen saturation (SPO2) reading of \< 90% on room air

Primary outcomes:
measure: Incidence of Early postoperative hypoventilation
timeFrame: UP to 24 hours Postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT01819571: Pulse Pressure Variation for Prediction of Fluid Responsiveness in Coronary Artery Disease Patients With Diastolic Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fluid Responsiveness Predictability
Keywords: pulse pressure variation
fluid responsiveness
diastolic dysfunction
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-03-27
Enrollment: 66
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators hypothesized that predictability of pulse pressure variation (PPV) on fluid responsiveness would be reduced in patients with coronary disease who have diastolic dysfunction.


Eligibility criteria: Inclusion Criteria:

* Patients older than 20 years
* scheduled for elective coronary artery bypass grafting
* normal diastolic function (E/E' \< 8) or diastolic dysfunction (E/E' \>15) according to preoperative Echocardiographic evaluation

Exclusion Criteria:

* arrythmia,
* reduced left ventricular function (ejection fraction \< 40%)
* valvular heart disease requiring concomitant surgical correction
* pulmonary hypertension (mean pulmonary arterial pressure ≥30 mm Hg)
* peripheral arterial occlusive disease, pulmonary disease (asthma, chronic obstructive pulmonary disease, and lung resection)
* end-stage renal disease

Primary outcomes:
measure: predictability of pulse pressure variation (PPV) on fluid responsiveness in patients with coronary disease who have normal diastolic function and diastolic dysfunction.
timeFrame: 10 minutes after fluid replacement
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of anesthesiology and pain medicine
Study officials:
References:
Clinical trial NCT03477071: A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis
Official title: A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis: Evaluation of Post-operative Outcomes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Unrecognized Condition
Keywords: Transplant renal artery stenosis
Endovascular repair
Post-operative outcome
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2018-03-26
Enrollment: 1323
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective, monocentric study included patients with peri-anastomotic stenosis of the renal graft from 2000 to 2017.

Brief summary: Stenosis of the renal graft arteries occurs in 1 to 26% of cases and can damage the graft. Endovascular treatment is first-line treatment. The main objective of this study is to identify the predictive factors of failure of peri-anastomotic.

Detailed description: The aim of this study was to evaluate the post-operative outcomes following endovascular treatment of TRAS (Transplant Renal Artery Stenosis).

This retrospective, monocentric study included patients with peri-anastomotic stenosis of the renal graft from 2000 to 2017. The stenosis is defined by a reduction of at least 50% of the arterial diameter during arteriography. Technical success was defined as residual stenosis less than 30% of the arterial diameter after the procedure.

Eligibility criteria: Inclusion Criteria:

* All patients who had a renal transplant from brain-dead donors or from living donors
* All patients who had a Transplant Renal Artery Stenosis

Exclusion Criteria:

* None

Primary outcomes:
measure: The technical success rate of endovascular treatment
timeFrame: 30 days
Secondary outcomes:
measure: Morbidity rate
timeFrame: 30 days
measure: Mortality rate
timeFrame: 30 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06786988: Cerebral Safety After Pulsed-Field Ablation of Atrial Fibrillation
Official title: Cerebral Safety After Pulsed-Field Ablation of Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Ischaemic Cerebral Infarction
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
First posted: 2025-01-22
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a common clinical indication for AF ablation.

Brief summary: A study evaluating the incidence of ischaemic lesions detected by brain MRI scan in subjects undergoing pulsed-field ablation for atrial fibrillation (VARIPULSE system).

Detailed description: An observational study evaluating the incidence of ischaemic lesions on brain MRI performed after ablation of atrial fibrillation using the Varipulse catheter.

1. A baseline MRI scan will be carried out one day before the procedure.
2. A post-procedure MRI scan will be performed 24-36 hours after the procedure.
3. A follow-up MRI will be performed within 1 year after the ablation.

Paroxysmal and non-paroxysmal AF patients will be included. Regarding the extent of ablation lesions, pulmonary vein isolation (PVI) will be performed in paroxysmal AF, whereas PVI + left atrial posterior wall ablation will be performed in non-paroxysmal patients. All procedures will be performed under intracardiac echocardiography guidance.

The patients will undergo a neurocognitive evaluation:

1. One day before the procedure: Montreal Cognitive Assessment (The MoCA Test)
2. 24-36 hours after the procedure: The National Institutes of Health Stroke Scale (NIHSS)
3. Up to 1 year after the procedure the MoCA test.

Eligibility criteria: Inclusion Criteria:

* AF with an indication for ablation

Exclusion Criteria:

* MRI contraindication

Primary outcomes:
measure: ischaemic lesion
timeFrame: one day before the procedure (the first MRI scan), 24-36 hour sfter the procedure (the second scan) and up to 1 year after the procedure (the third scan)
Secondary outcomes:
measure: Neurocognitive evaluation
timeFrame: one day before the procedure (the first MoCA test) and up to 1 year after the procedure (the second MoCA test)
measure: NIHSS score
timeFrame: 24-36 hours after the procedure
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06503588: Ureteral Stent Exchange Abstention in Urinary Tract Infections
Official title: Ureteral Stent Exchange Abstention in Urinary Tract Infections: a Before-and-after Study to Assess Guidelines' Impact on Patients' Outcomes
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Urinary Tract Infections
Urinary Catheterization
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2024-07-16
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Groups will be selected from patients attending University Hospital of Nancy meeting the eligibility criteria during the period of inclusion running from January 1, 2018 to May 31, 2020 and from August 1, 2020 to December 31, 2022

Brief summary: The Committee of Infectiology of the French Association of Urology (CIAFU) provided, for the first time in 2020, comprehensive guidelines for ureteral stent-associated urinary tract infections (USAUTI) prevention, diagnosis and treatment. Since evidence lacked in terms of appropriate treatment, guidelines could not support systematic change of US in case of USAUTI.

This study aims to evaluate whether "after guidelines group" patients treated for USAUTI had different occurrence of at least one relapse or recurrence than "before guidelines group".


Eligibility criteria: Inclusion Criteria:

* All patients with indwelling ureteral catheter
* AND confirmed or probable urinary tract infection

Exclusion Criteria:

* Patient's opposition
* History of ileal conduit urinary diversion
* Second or more urinary tract infection during the study period

Primary outcomes:
measure: Relapse OR recurrence of urinary tract infection
timeFrame: 1 year
Secondary outcomes:
measure: Nephro-urologic complication
timeFrame: 1 year
measure: Infectious complication
timeFrame: 1 year
measure: In-hospital and 1-year mortality
timeFrame: 1 year
measure: Resort to Watch or Reserve antibiotics
timeFrame: 1 year
Other outcomes:
Locations:
city: Nancy
country: France
facility: Nancy university hospital
state: Lorraine
Study officials:
affiliation: Central Hospital, Nancy, France
name: +33383154097 Lefevre, M.D. PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00507078: Biomarkers in Obstructive Sleep Apnea Surgery
Official title: Biomarkers in Obstructive Sleep Apnea Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Keywords: Obstructive Sleep Apnea
Leptin
Homocysteine
C-reactive Protein
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2007-07-25
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Recent years have witnessed major advances in the understanding of the hormonal, metabolic, and biochemical changes that occur in obstructive sleep apnea (OSA). This project evaluates the biomarkers that measure the most significant health impacts of this disorder and creates a specimen bank that will facilitate evaluations of additional biomarkers in the future.

Detailed description: This is a case-control study to examine the relationship between obstructive sleep apnea (OSA) and elevated levels of leptin, homocysteine, and C-reactive protein (CRP) in moderate or severe OSA and control patients. This is followed by a prospective cohort study to examine the relationship between surgical treatment of moderate or severe OSA and serum levels of these biomarkers.

The short-term goals of this study consider the abnormalities in biomarker levels associated with OSA and specific aspects of the disorder as well as whether the changes seen after surgical treatment of OSA mirror those demonstrated after efficacious non-surgical treatment. The long term goals are in two areas: 1) the development of measures to determine which patients require treatment for sleep-disordered breathing and to monitor the effectiveness of therapy, and 2) a deeper understanding of the connection between OSA and its adverse health consequences.

Eligibility criteria: Inclusion Criteria:

* OSA group is adults with moderate or severe OSA (apnea \>= 15 based on preoperative sleep study) undergoing surgical treatment. Assessment is done prior to surgery.
* Control group is overweight (body mass \>25) adults without OSA (apnea-hypopnea index \<5 based on sleep study) or other sleep disorders. Assessment is prior to treatment.

Primary outcomes:
measure: Leptin, homocysteine, and C-reactive protein levels.
timeFrame: Before and after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
Study officials:
affiliation: University of California, San Francisco
name: Eric Kezirian, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00113178: Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial Flutter
Official title: Clinical Study to Evaluate the Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Cavo-Tricuspid Valve Isthmus-Dependent Atrial Flutter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atrial Flutter
Keywords: atrial flutter
cryoablation
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2005-06-07
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of right atrial intra-cardiac lesions created by transvenous catheter cryoablation in patients with atrial flutter.

Detailed description: Catheter ablation of arrhythmias has become an accepted alternative to pharmacologic therapy. Cryoablation is a newer alternative to radiofrequency ablations. This study expands the prior pilot experience with the CryoCor™ Cardiac Cryoablation System to a larger cohort of patients with atrial flutter.

Eligibility criteria: Inclusion Criteria:

* Symptomatic atrial flutter

Exclusion Criteria:

* Prior ablation
* Contraindication to intervention
* Poor general health

Primary outcomes:
measure: Acute efficacy
measure: Acute safety
Secondary outcomes:
measure: Long-term efficacy
measure: Long-term safety
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04299178: Usability Evaluation of a Portable Oxygen Concentrator
Official title: Human Factors Validation Testing for Use of the Belluscura X-PLO2R™ Portable Oxygen Concentrator (POC) System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Supplemental Oxygen
Lead sponsor: Belluscura LLC
Sponsor class: INDUSTRY
First posted: 2020-03-06
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population It is patients requiring supplemental oxygen, as prescribed by a physician.

Brief summary: This study evaluates how well an individual can put together and use a Portable Oxygen Concentrator (POC) by following the instructions in the User Manual.

Detailed description: The Belluscura X-PLO2R Portable Oxygen Concentrator (POC) is intended for the provision of supplemental oxygen to patients with chronic pulmonary diseases, such as Chronic Obstructive Pulmonary Disease (COPD), and for a patient requiring supplemental oxygen, as prescribed by a physician. The purpose of this study is to evaluate if the X-PLO2R POC can be used by the intended users without serious errors or problems for the intended use and under the expected use conditions. Specifically, the study is to evaluate if potential users of the device can correctly, safely and effectively set-up, activate and operate the X-PLO2R POC to receive the required supplemental oxygen; if the intended user can understand and apply the information contained in the Belluscura X-PLO2R Quick Start Guide and User Manual; and to identify any and all use difficulties, problems and errors made during device assembly and operation, and to subsequently mitigate each identified instance of use error through device and/or materials modification, and to subsequently evaluate the effectiveness of each modification.

Eligibility criteria: Inclusion Criteria:

* 18 years or older.
* Male or female.
* Suitable for supplemental oxygen use from a suitably qualified and licensed medical professional.
* Voluntarily signed subject consent form.

Exclusion Criteria:

* Company employee.
* Former human factors study participants.

Primary outcomes:
measure: Ability to correctly assemble and use the X-PLO2R POC
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Plano
country: United States
facility: Belluscura LLC
state: Texas
Study officials:
name: Elvira Cawthon, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06906978: Single Cell Acute Leukemia Analysis
Official title: Single Cell Acute Leukemia Analysis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acute Myeloid Leucemia
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2025-04-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.


Eligibility criteria: Inclusion Criteria:

* Adult patient
* Patient who has received information about the study and has not expressed opposition,
* Patients who are beneficiaries of a social security plan,
* Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.

Exclusion Criteria:

* Persons who do not understand the French language if there is no translator available to translate for them.
* Absence of circulating blastosis.

Primary outcomes:
measure: percentage of leukemic blasts coexpressing P-glycoprotein (PGP)-Multidrug resistance-related protein (MRP)+ Glutathione S-transferase (GST)+ anti- B-cell Lymphoma 2 (BLC2)
timeFrame: 36 months
Secondary outcomes:
measure: percentage of P-glycoprotein (PGP)-Multidrug resistance-related protein (MRP)+ Glutathione S-transferase (GST)+ anti- B-cell Lymphoma 2 (BLC2) coexpression in leukemic blasts
timeFrame: 36 months
Other outcomes:
Locations:
Study officials:
affiliation: Assitance Public - Hôpitaux de Marseille
name: Régis Costello, Professor
role: PRINCIPAL_INVESTIGATOR
References: